Nakano, Tomoyuki http://orcid.org/0000-0003-0933-1714
Shigeta, Keigo
Ota, Takahiro
Amano, Tatsuo
Ueda, Masayuki
Matsumaru, Yuji
Shiokawa, Yoshiaki
Hirano, Teruyuki
Funding for this research was provided by:
Japanese Society for Neuroendovascular Therapy
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi-Sankyo
Otsuka Pharma
Pfizer
Sanofi
Medtronic
Stryker
Johnson and Johnson
AbbVie GK
ONO Pharmmedical Co., LTD.
Article History
Received: 19 April 2019
Accepted: 7 June 2019
First Online: 23 July 2019
Compliance with ethical guidelines
:
: T. Nakano, K. Shigeta, T. Ota, T. Amano and M. Ueda declare that they have no competing interests. Y. Matsumaru received honoraria from Medtronic, Stryker, and Johnson&Johnson. Y. Shiokawa received research grant from AbbVie GK and ONO Pharmmedical Co., LTD. T. Hirano received honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Otsuka Pharma, Pfizer, and Sanofi.
: Each hospital provided individual patient data with the approval of their institutional review boards. The study adhered to the ethical principles that have their origin in the Declaration of Helsinki. Informed consent was obtained in the form of opt-out in each hospital.